Chemoembolization of the liver in Israel — get 3 personalized clinic matches

Chemoembolization or TACE is a minimally invasive treatment for liver cancer that combines local chemotherapy with blood flow blockage. Interventional radiologists in Israel insert catheters into the hepatic artery to deliver drugs directly to tumors, preserving healthy tissue while starving cancer cells of oxygen.

• Procedure technique: Surgeons use fluoroscopy to guide catheters through the femoral artery or arm.
• Treatment mechanism: Chemotherapy agents like doxorubicin are trapped in tumors using embolic beads.
• Hospital stay: Patients typically stay 1–3 days for monitoring post-embolization syndrome symptoms.
• Treatment cycle: Most medical plans involve 3–4 staged sessions spaced 4–6 weeks apart.

Bookimed Expert Insight: Israeli oncology centers like Sourasky or Assuta often favor superselective TACE. This precise approach targets only the smallest feeding vessels. By protecting more healthy liver tissue, these clinics can maintain better liver function for patients requiring multiple treatment rounds.

Patient Consensus: Expect flu-like symptoms for about a week. Many verify beforehand if they will receive doxorubicin-eluting beads (DEB-TACE), as this can sometimes cause more initial discomfort than standard protocols.

Transarterial Chemoembolization (TACE) offers a targeted alternative to systemic chemotherapy by delivering high-dose drugs directly into liver tumors while blocking their blood supply. This dual-action approach minimizes systemic toxicity, preserves healthy liver function, and serves as the standard care for unresectable intermediate-stage cancer.

• Targeted potency: Delivers drug concentrations up to 600% higher than systemic treatments.
• Reduced toxicity: Minimizes systemic side effects like hair loss and immune suppression.
• Ischemic effect: Blocks blood flow to starve the tumor of oxygen.
• Preserved function: Image-guided precision helps protect surrounding healthy liver tissue.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center utilize multidisciplinary tumor boards to evaluate TACE candidacy. Data shows centers treating 40,000 yearly patients favor TACE for localized tumors. This clinical volume ensures surgeons maintain the high precision needed for catheter placement.

Patient Consensus: Patients report that while post-embolization syndrome causes short-term discomfort, the recovery is more manageable than chronic systemic fatigue. Follow-up scans often show successful tumor core inactivation even when outer edges remain visible.

Transarterial chemoembolization (TACE) in Israel achieves objective response rates between 52.5% and 57.4% for intermediate-stage liver cancer. This treatment significantly extends median survival to over 20 months compared to 4–8 months with supportive care. Success often requires high-volume JCI-accredited centers like Sourasky Medical Center.

• Survival rates: Approximately 70.3% to 91.8% of patients reach the 1-year survival milestone.
• Tumor control: Disease control rates reach 89.7% when surgeons combine TACE with other therapies.
• Treatment frequency: TACE is repeatable, maintaining a 58% response rate during a third session.
• Hospital stay: Patients typically require an overnight stay at facilities like Assuta Medical Center.

Bookimed Expert Insight: Israeli oncology centers like Sourasky treat 40,000 cancer patients annually, creating a massive data pool for long-term outcomes. While many clinics offer standard TACE, leading Tel Aviv hospitals prioritize DEB-TACE (drug-eluting beads). This approach provides more sustained tumor control and predictable drug release than conventional methods.

Patient Consensus: Most patients view TACE as a vital bridge to transplantation or a long-term control strategy. While they report flu-like symptoms for one week, the significant tumor shrinkage provides huge relief.